Itziar Casado

Has grant

Instituto de Salud Pública de Navarra

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

CIBER Epidemiología y Salud Pública

Open Date:

Close Date:

Articles (18)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (13)

Heather Whitaker

Open University

UNITED KINGDOM

View details

Irina Kislaya

Bernhard Nocht Institute for Tropical Medicine

GERMANY

View details

Marcela Guevara

Instituto de Salud Pública de Navarra

SPAIN

View details

Luise Goerlitz

Robert Koch Institute

GERMANY

View details

Clara Mazagatos

Instituto de Salud Carlos III

SPAIN

View details

Iván Martínez-Baz

Profesor asociado

Universidad de Navarra

SPAIN

View details

Jesus Castilla

Instituto de Salud Pública de Navarra

SPAIN

View details

Ana Paula Rodrigues

Instituto Nacional de Saúde Doutor Ricardo Jorge

PORTUGAL

View details

Amanda Bolt Botnen

Statens Serum Institut

DENMARK

View details

Noelia Vera Punzano

Instituto de Salud Pública de Navarra

SPAIN

View details

Patricia Soares

PORTUGAL

View details

Hinta Meijerink

Norwegian Institute of Public Health

NORWAY

View details

Thierry BLANCHON

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Itziar Casado

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (18)

Hospitalisation due to respiratory syncytial virus in a population-based cohort of older adults in Spain, 2016/17 to 2019/20

Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021–2022

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.

Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023/24 season: A population-based test-negative case-control study

Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023.

Influenza Vaccine Effectiveness in Preventing Laboratory-Confirmed Influenza Cases and Hospitalizations in Navarre, Spain, 2022–2023

Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022

Comparison of the Risk of Hospitalization and Severe Disease Among Co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variants

Effect of COVID-19 vaccination on the SARS-CoV-2 transmission among social and household close contacts: A cohort study

Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I-MOVE primary care multicentre study

Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.

[COVID-19 infections, hospitalizations, and mortality in Navarre (Spain) between February 2020 and September 2022].

Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.

Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned

Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022

Effectiveness of influenza vaccination in preventing influenza in primary care, Navarre, Spain, 2021/22

Collaborators (13)

Heather Whitaker

Irina Kislaya

Marcela Guevara

Luise Goerlitz

Clara Mazagatos

Iván Martínez-Baz

Jesus Castilla

Ana Paula Rodrigues

Amanda Bolt Botnen

Noelia Vera Punzano

Patricia Soares

Hinta Meijerink

Thierry BLANCHON

Make your next move.

Itziar Casado

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (18)

Hospitalisation due to respiratory syncytial virus in a population-based cohort of older adults in Spain, 2016/17 to 2019/20

Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021–2022

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.

Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023/24 season: A population-based test-negative case-control study

Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023.

Influenza Vaccine Effectiveness in Preventing Laboratory-Confirmed Influenza Cases and Hospitalizations in Navarre, Spain, 2022–2023

Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022

Comparison of the Risk of Hospitalization and Severe Disease Among Co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variants

Effect of COVID-19 vaccination on the SARS-CoV-2 transmission among social and household close contacts: A cohort study

Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I-MOVE primary care multicentre study

Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.

[COVID-19 infections, hospitalizations, and mortality in Navarre (Spain) between February 2020 and September 2022].

Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.

Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned

Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022

Effectiveness of influenza vaccination in preventing influenza in primary care, Navarre, Spain, 2021/22

Collaborators (13)

Heather Whitaker

Irina Kislaya

Marcela Guevara

Luise Goerlitz

Clara Mazagatos

Iván Martínez-Baz

Jesus Castilla

Ana Paula Rodrigues

Amanda Bolt Botnen

Noelia Vera Punzano

Patricia Soares

Hinta Meijerink

Thierry BLANCHON

Make your next move.

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.